男性乳腺癌约占全球所有乳腺癌病例的1％。尽管治疗转移性乳腺癌（MBC）的阿贝马西利布在女性中应用丰富，但在男性MBC中缺乏现实世界的证据。本分析是一项更广泛的回顾性研究的一部分，分析了448名男性和女性的电子病历和图表，这些人患有激素受体阳性（HR +）、人表皮生长因子受体2阴性（HER2-）的MBC，并在2017年1月至2019年9月期间启动了含阿贝马西利布的方案。数据来源于佛罗里达癌症专家和研究所和电子医疗办公室物流健康肿瘤仓库语言™数据库，并进行描述性总结。对使用阿贝马西利布联合芳香化酶抑制剂（AI）或富莫司汀治疗的6名男性乳腺癌患者的数据进行了呈现。其中四位患者年龄在75岁或以上，有四位患者有≥3个转移部位，包括内脏受累。四名患者在≥3L中开始使用阿贝马西利布，患者曾经历过在转移性情况下使用AI（n = 4）、化疗（n = 3）和/或前文聚焦激酶4和6抑制剂（n = 2）的治疗史。阿贝马西利布+富莫司汀是最常见的含阿贝马西利布的方案（n = 4）。四位患者中有一个患者为CR，一个为PR，一个为SD，一个为PD。该数据集中男性MBC的流行病学与更广泛人群的预期流行病学一致。大多数男性患者在≥3L中接受了含阿贝马西利布的方案，尽管有大量的转移负担和原来的治疗，但观察到了抗癌活性。© 2023. 作者（们）。

Breast cancer in males constitutes approximately 1% of all breast cancer cases globally. Despite extensive treatment experience with abemaciclib in women with metastatic breast cancer (MBC), real-world evidence in male MBC is lacking.This analysis was a part of a broader, retrospective study that analyzed electronic medical records and charts of 448 men and women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) MBC who initiated an abemaciclib-containing regimen from January 2017 through September 2019. Data were collected from the Florida Cancer Specialists & Research Institute and the Electronic Medical Office Logistics Health Oncology Warehouse Language™ databases and summarized descriptively. Real-world best response was described: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD).Data for six male patients with MBC who were treated with abemaciclib in combination with an aromatase inhibitor (AI) or fulvestrant are presented. Four patients were aged ≥ 75 years, and four patients had ≥ 3 metastatic sites, including visceral involvement. Abemaciclib was initiated in/after third-line (≥ 3L) in four patients, and patients had history of treatment with AI (n = 4), chemotherapy (n = 3), and/or prior cyclin-dependent kinase 4 and 6 inhibitors (n = 2) in the metastatic setting. Abemaciclib + fulvestrant was the most common abemaciclib-containing regimen (n = 4). Best response was documented in four patients: 1 each with CR, PR, SD, and PD.Prevalence of male MBC in this dataset was consistent with expected prevalence in the broader population. Most male patients received an abemaciclib-containing regimen in ≥ 3L, with anti-cancer activity observed despite heavy metastatic burden and prior treatments in a metastatic setting.© 2023. The Author(s).